Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

SBIR Reauthorization Moves Forward

SBIR Reauthorization Moves Forward

NIH has reissued its Small Business Innovation Research (SBIR) Omnibus Grant Solicitation announcement, which states that small businesses that are majority-owned by multiple venture capital operating companies are eligible to apply for (1) these SBIR grants and (2) any other NIH SBIR funding opportunities announced after January 28, 2013.  The NIH grant solicitation announcement can be found here. With this re-issuance, small businesses that are majority-owned by multiple venture capital operating companies (VCOCs), hedge funds Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

Inside Health Policy: Clearing Up Confusion About Bills Updating Vaccine Tax Code

Syringes

Inside Health Policy’s Alaina Busch wrote a story today on confusion that has been spreading recently related to vaccines excise legislation. Vaccines protect people from seasonal flu, and new strains have recently been approved to further protect public health. As such, the vaccine excise tax must in turn be updated to include recent approvals. S. 391 and H.R. 475 update the existing excise tax to cover the newest seasonal influenza vaccines. The legislation does not Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

How Countries Can Boost Their Biotech Industry

Field

How can countries and regions boost the biotech industry within their borders? Working with several member companies, BIO developed a Global Policy Platform to serve as a roadmap for policymakers seeking to create an environment for the biotech industry to grow and prosper. These policy principles include four components: (i) research collaboration; (ii) intellectual property rights; (iii) regulatory approval; and (iv) market access. In addition, the Global Policy Platform includes best practices from around the Read More >

Corporate  |  1 Comment  |  Email This Post
Tags: , , , ,

Show Me the Money: Reimbursement in an ACA World

BIO CEO 2013

A panel at the BIO CEO & Investor Conference focused on reimbursement discussed value from a variety of perspectives and agreed that the landscape is shifting dramatically. The reimbursement roundtable featured payors, providers, and other stakeholders discussing Affordable Care Act (ACA) implementation and the wider reimbursement landscape. With many key provisions of the ACA slated to take effect in 2013 and beyond, the industry is facing sweeping changes to the managed care and reimbursement road map. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Orphan Drugs: Making Rare Diseases Rarer

Panel

A panel at the BIO CEO & Investor Conference provided an analysis of the thriving orphan drug market opportunity featuring industry, clinical and regulatory experts specializing in rare diseases. The signing of FDASIA by President Obama in July reinforces the country’s commitment to fostering innovation for rare diseases. With a record 460 medicines in late-stage clinical trials, biopharmaceutical companies have embraced rare disease medicine and are rapidly developing the pipeline with hopes of achieving the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,